HER2 directed therapy for gastric/esophageal cancers Journal Article


Authors: Won, E.; Janjigian, Y.; Ilson, D. H.
Article Title: HER2 directed therapy for gastric/esophageal cancers
Abstract: OPINION STATEMENT: The majority of patients with esophagogastric cancer present with advanced disease, which is incurable. Systemic chemotherapy can lead to a decrease in cancer-related symptoms and prolongs survival. However, even with treatment, the prognosis remains poor; most patients with advanced disease have a median overall survival less than one year. Molecularly targeted therapies, such as those targeting human epidermal growth factor receptor 2 (HER2), are anticipated to improve the current status of systemic treatment beyond conventional cytotoxic therapy. Trastuzumab in combination with chemotherapy in patients is the first molecular agent in metastatic HER2 positive gastric and gastroesophageal adenocarcinomas to result in improvements in response rates, time to progression and survival. Trastuzumab is now being investigated in the neoadjuvant and adjuvant setting. Unfortunately, as with breast cancer, many esophagogastric patients will develop resistance to trastuzumab. Several promising therapies are currently under investigation as monotherapy and in combination with chemotherapy in the first and second line setting.
Keywords: antineoplastic agents; antineoplastic agent; metabolism; antineoplastic combined chemotherapy protocols; epidermal growth factor receptor 2; drug resistance; drug resistance, neoplasm; monoclonal antibody; diet; receptor, erbb-2; trastuzumab; stomach neoplasms; esophageal neoplasms; lifestyle; life style; molecularly targeted therapy; molecular targeted therapy; antibodies, monoclonal, humanized; humans; prognosis; human; antagonists and inhibitors
Journal Title: Current Treatment Options in Oncology
Volume: 15
Issue: 3
ISSN: 1527-2729
Publisher: Springer  
Date Published: 2014-09-01
Start Page: 395
End Page: 404
Language: English
DOI: 10.1007/s11864-014-0292-6
PUBMED: 24811128
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 3 June 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Yelena Yuriy Janjigian
    394 Janjigian
  2. David H Ilson
    433 Ilson
  3. Elizabeth Siryeon Won
    41 Won
Related MSK Work